AstraZeneca equity investment in Summit Therapeutics
Primary Investment28/09/2026
Agreement for an equity investment in Summit Therapeutics. Subsequently completed on 5 October 2026, as disclosed in the completion release and Q3 report. Clinical collaborations evaluate drug combinations; efficacy is not established by this transaction.
Type
Primary Investment
Announced
28/09/2026
Amount
Financial data requires access
Reported parties
AstraZeneca PLC,Summit Therapeutics Inc.